Alembic Pharmaceuticals Limited today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Empagliflozin and Linagliptin Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Linagliptin is appropriate.
Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of Empagliflozin and Linagliptin Tablets on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established. Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg have an estimated market size of US$ 244 million for twelve months ending June 2020 according to IQVIA.
Alembic is currently in litigation with Boehringer in District Court of Delaware and launch of the product will depend on litigation outcome. Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from USFDA.
Five-year partnership with Genesys enables both companies to develop and deploy innovation and bestin-class solutions in the CX market
Infosys today announced the launch of a partnership with Genesys®, a global leader in cloud customer experience and contact center solutions. The alliance will position both organizations to enhance and expand their customer experience and contact center offerings. Together, the companies will deliver market-disrupting innovation and mission-critical support to enable organizations around the world to provide differentiated customer service experiences.
As a part of the partnership, Infosys will bring to market Genesys contact center solutions. Clients of both organizations stand to benefit from the enhanced capability that will come from a combined investment in innovation, a broader ecosystem of strategic partners and a shared commitment to delivering world-class customer experiences. In addition, Infosys will leverage and support R&D, operations and customer service for Genesys PureConnect™. Genesys will retain and manage sales, marketing and a host of additional functions for this solution
A meeting of the Board of Directors of the Company is scheduled on Monday, August 31, 2020 to seek approval for raising funds by issue of securities including debt securities, subject to receipt of the necessary approvals including the approval of the shareholders (as applicable) and other regulatory / statutory approvals, as may be required.
The meeting of the Board of Directors of the Company is scheduled to be held on Saturday, 29th August, 2020 to consider and evaluate proposals to raise funds by way of issuance of bonds including debentures / non-convertible debt instruments / securities and/or any other instruments / securities including through private placement or through any other permissible mode or any combination thereof, as may be decided by the Board and subject to such statutory / regulatory approvals as may be necessary, including the approval of the shareholders of the Company, wherever required.
- Partnership to leverage REE’s corner module and modular platform technology and Mahindra’s vehicle design, engineering, sourcing capability and manufacturing assets.
- MOU is primarily aimed at global markets with current global volume estimated over time at 200,000- 250,000 units.
Mahindra & Mahindra and REE Automotive today signed a memorandum of understanding (MOU) to explore development and manufacturing of electric commercial vehicles for global markets.
Such a strategic collaboration will leverage REE’s revolutionary electric vehicle corner module and platform technology of integrating powertrain, suspension and steering components in the arch of a vehicle wheel. This coupled with Mahindra’s well-established vehicle design, engineering, sourcing capability and manufacturing assets, is set to be a win-win strategic partnership for both companies.
The partnership will support REE’s global customer need for 200,000-250,000 electric commercial vehicle units over a few years, including potential Mahindra’s domestic and international volumes. Production would be scaled further to support additional volume in the global as well as Indian market.
- Nepexto® is Lupin’s biosimilar etanercept approved for all indications of the reference product Enbrel®
- Nepexto® is available as an injectable in an easy-to-use pre-filled pen and a pre-filled syringe
- The approval of Nepexto® by the European Medicines Agency (EMA) underlines the scientific success of Lupin’s biosimilar programs
Lupin Limited (Lupin) and Mylan N.V. announced today the launch of Nepexto® , biosimilar etanercept, in the German market. Nepexto® is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis from the age of 2 years, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents from the age of 6 years. Nepexto® is approved for all therapeutic indications of the reference product Enbrel®.
Brahmaputra Infrastructure Limited along with its JV Partners has received the below mentioned projects from Ajmer Smart City Limited.
- JCC Infra Projects BIL JV, has bagged order worth of Rs. 36.22 Crores for execution of the work of “Construction of Medicine Block at JLN hospital Ajmer”.
- JCC Infra Projects BIL JV, has bagged order worth of Rs. 28.08 Crores for execution of the work of “Construction of Pediatrics Block and Multilevel Parking at JLN Hospital, Ajmer”
Board has decided to participate in coal block auction process with a view to profitably mine and sell coal commercially, while deploying best in class technology, equipment and practices, with a focus on emerging clean coal technologies with low to zero emissions through carbon capture, utilization and storage.
Company will continue to explore more opportunities to enhance shareholder value.
Full read: RattanIndia Infrastructure coal mining decision by Board.pdf (70.94 kb)
Affle International Pte. Ltd., today announced that it has won the contract from the Singapore Government to build a ‘Digital & Cloud-based Commuter Survey Platform’ for Land Transport Authority (LTA).
Affle’s mobile marketing platforms will enable interactive surveys for citizens in Singapore to drive LTA’s objective of building a people-centered land transport system. The total value of the contract is over US$ 1 million. Affle’s platforms were first accredited by the Infocomm Media Development Authority of Singapore in 2018, and Affle is actively engaged on 6 projects across multiple Singapore government agencies as on date.
The Board of Directors of the Bank shall consider the Raising of Capital (Tier I/Tier II) to the tune of INR 4,500 Crores during the Financial Year 2020-2021, in the meeting scheduled for August 28, 2020.
The Board of Directors of the company at their meeting held today has approved:
1) Report on opportunities available for the company in Pharmaceutical, API & chemical industry
2) Investment of INR 75 crores over next 2 years in the new businesses identified, form JVs or strategic partnerships if required and find ways of organic and inorganic growth
- To treat mild to moderate cases
FDC Limited, today announced its foray in the fight against COVID-19 by launching two variants of the COVID-19 drug, Favipiravir – PiFLU and Favenza – which will be used to treat mild to moderate cases of COVID-19 in India.
Earlier this year, the Drug Controller General of India (DCGI) approved the use of Favipiravir, an off patent, oral anti-viral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms. It is a broad spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication.
FDC’s PiFLU and Favenza is currently available across the country.
Va Tech Wabag has announced that its Board of Directors has considered the Letters of Consent received from the following marquee, high networth investors and approved the infusion of equity capital into the Company.
- Rekha Rakesh Jhunjhunwala
Value: INR 80 Crores
- Basera Home Finance Private Limited
Value: INR 24 Crores
- Sushma Anand Jain &
Anand Jaikumar Jain
Value: INR 16 Crores
The above issue of Equity Shares on Preferential basis to aforesaid Proposed Investors, are subject to the approval of the Members of the Company at the ensuing Annual General Meeting scheduled to be held on Wednesday, September 23, 2020.
JMC Projects (India) Limited (JMC), a leading Civil Engineering and EPC Company has secured new orders of Rs. 554 Crores.
- Building Project in South India totalling Rs.315 Crores
- Factory Project in Maharashtra of Rs.239 Crores
The Company is considering various options for raising funds through borrowings including by the way of issuance of various debt securities in onshore / offshore securities market by Public Issue, Private Placement Basis and Commercial Papers. Based on the prevailing market conditions, Financial Resources and Management Committee / Debenture Committee of the Board of Directors of the Company may consider and approve issuances of Debt Securities during the month of September, 2020, subject to such terms and conditions including the issue price of debt securities, as the respective committee may deem fit
Ramco Systems has signed up a multi-million Dollar agreement with a leading utilities and infrastructure Group with diversified businesses in Malaysia for delivering Group-wide Digital Transformation spanning across its ports and logistics operations. With this win, Ramco’s enterprise platform will support in managing more than 50% of all port operations in Malaysia.
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desonide Lotion, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), DesOwen® Lotion, 0.05% of Galderma Laboratories LP. Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Desonide Lotion, 0.05% has an estimated market size of US$ 7 million for twelve months ending June 2020 according to IQVIA.
Alembic has a cumulative total of 129 ANDA approvals (113 final approvals and 16 tentative approvals) from USFDA.
CARE Ratings has upgraded Dish TV's credit rating for the following instrument(s):
- Instrument: Short-term
- Rated amount: INR 600 crores
- New rating: CARE A4
- Existing rating: CARE D